These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26506619)

  • 1. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
    Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
    PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma.
    Havranek O; Spacek M; Hubacek P; Mocikova H; Markova J; Trneny M; Kleibl Z
    Neoplasma; 2011; 58(5):392-5. PubMed ID: 21744992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
    Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
    Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
    Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z
    Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
    Złowocka E; Cybulski C; Górski B; Debniak T; Słojewski M; Wokołorczyk D; Serrano-Fernández P; Matyjasik J; van de Wetering T; Sikorski A; Scott RJ; Lubiński J
    Int J Cancer; 2008 Feb; 122(3):583-6. PubMed ID: 17918154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma.
    Wang SS; Davis S; Cerhan JR; Hartge P; Severson RK; Cozen W; Lan Q; Welch R; Chanock SJ; Rothman N
    Carcinogenesis; 2006 Sep; 27(9):1828-34. PubMed ID: 16543247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut.
    Shen M; Zheng T; Lan Q; Zhang Y; Zahm SH; Wang SS; Holford TR; Leaderer B; Yeager M; Welch R; Kang D; Boyle P; Zhang B; Zou K; Zhu Y; Chanock S; Rothman N
    Hum Genet; 2006 Jul; 119(6):659-68. PubMed ID: 16738949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival from breast cancer in patients with CHEK2 mutations.
    Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
    Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
    Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of two mutations in the CHEK2 gene with breast cancer.
    Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T
    Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHEK2 mutations and the risk of papillary thyroid cancer.
    Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
    Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.
    AlDubayan SH; Pyle LC; Gamulin M; Kulis T; Moore ND; Taylor-Weiner A; Hamid AA; Reardon B; Wubbenhorst B; Godse R; Vaughn DJ; Jacobs LA; Meien S; Grgic M; Kastelan Z; Markt SC; Damrauer SM; Rader DJ; Kember RL; Loud JT; Kanetsky PA; Greene MH; Sweeney CJ; Kubisch C; Nathanson KL; Van Allen EM; Stewart DR; Lessel D;
    JAMA Oncol; 2019 Apr; 5(4):514-522. PubMed ID: 30676620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
    Stubbins RJ; Korotev S; Godley LA
    Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.